Bristol-Myers Squibb and Gilead Sciences have entered a licensing agreement for the development and commercialisation of a new fixed-dose combination pill for HIV-infected patients.

The combination pill includes Bristol-Myers’ protease inhibitor Reyataz (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing agent that increases blood levels of certain HIV medicines to enable a dosing of one pill per day.

Reyataz is a prescription drug used in combination with other medicines to treat HIV infected patients aged six or older, and cobicistat is a mechanism-based inhibitor of cytochrome P450 3A, an enzyme that metabolises drugs in the body.

Under the deal, Bristol-Myers will pay Gilead an undisclosed royalty based on annual net sales of the product.

Under the agreement, Bristol-Myers will be responsible for the commercialisation, development, distribution, formulation, manufacturing and registration of Reyataz and cobicistat as a fixed-dose combination.

Gilead will retain exclusive rights to manufacture, develop and market cobicistat as a stand-alone drug and for use in combination with other agents.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.